Why Is Azenta (AZTA) Stock Down -23% Today?
Key Takeaways
- AZTA shares plunged 23.82% to close at $18.75 from the previous close of $24.61.
- Primary catalyst: Q2 fiscal 2026 earnings miss, with revenue of $145 million missing estimates of $148.75 million and non-GAAP EPS loss of $0.04 versus expected $0.11 profit.
- Secondary drivers: $149 million non-cash goodwill impairments, gross margin contraction to 42.8%, and lowered FY2026 guidance for organic revenue to -2% to +1%.
- Trading volume elevated at 964,691 shares versus average of around 900,000, indicating strong selling pressure amid healthcare sector softness.
- Move diverged negatively from broader biotech ETFs like IBB and XBI, which saw milder declines.
- Traders watching execution improvements, Multiomics transformation, and Q3 results in August.
Breaking Down AZTA's Sharp Decline
I've been keeping an eye on AZTA, the provider of sample management and multiomics solutions for the life sciences industry, and its stock took a significant hit recently. Shares plummeted 23.82% in the latest trading session, closing at $18.75 after the prior close of $24.61. From what I see, this move was triggered by disappointing Q2 fiscal 2026 results released before the market open, which exposed some execution shortfalls and softer demand than anticipated.
Digging into the Q2 Earnings
Azenta's Q2 revenue from continuing operations came in at $145 million, marking just a 1% year-over-year increase but a 3% organic decline after adjusting for foreign exchange and the UK Biocentre acquisition. This missed analyst expectations of $148.75 million. Non-GAAP diluted EPS showed a loss of $0.04, well below the forecasted $0.11 profit and a reversal from the prior year's $0.01 gain. Adjusted EBITDA fell 36% to $8 million, with margins shrinking 320 basis points to 5.4%, driven by lower fixed-cost absorption, costs from Automated Stores rework, and inventory reserves.
One thing that stands out is the cautious demand environment, especially in North America, where Sanger Sequencing for Multiomics and core Sample Management products like Automated Stores and Cryogenic Systems saw declines. Adding to the pressure, the company recorded a $149 million non-cash goodwill impairment—$112.4 million in Multiomics and $36.6 million in Sample Management—which pushed GAAP earnings into an operating loss of $165.8 million. I also checked this using Tickeron’s AI Screener to gauge how AZTA stacks up against industry peers on these metrics.
The Revised FY2026 Outlook
Management didn't stop at reporting the miss; they also cut the full-year FY2026 guidance significantly. Total reported revenue is now expected at $603–$621 million, with organic growth adjusted to -2% to +1% from the previous 3–5% range. Sample Management growth is projected at low-single-digits rather than mid-single-digits, while Multiomics faces a mid-single-digit decline. Adjusted EBITDA margins are forecasted to be down 125 basis points to flat, compared to prior expansion expectations. Free cash flow guidance softened to a 10–15% improvement. In my view, this reflects execution gaps and demand caution, leading to leadership changes and a sharper operational focus.
Trading Volume and Market Reaction
Trading volume jumped to 964,691 shares, exceeding the average of about 900,000, which underscores the strong investor reaction to the earnings shortfall. AZTA's drop diverged sharply from broader indices, which closed only modestly lower, and biotech ETFs like IBB and XBI, which experienced smaller declines. The stock broke through key technical support around $23–$24, near its recent moving averages, and approached the 52-week low of $19.87, amplifying downside momentum in the healthcare equipment sector.
Spotlight on Trending AI Robots
In my own research process, I often turn to Tickeron’s Trending AI Robots to identify top-performing AI-driven trading bots suited to current conditions. The platform features hundreds of these bots scanning thousands of tickers across strategies like momentum, mean reversion, and sector plays. The trending section curates the strongest live performers, which has been particularly useful amid volatility such as this biotech sell-off. I find it helps pinpoint automated tools with a real edge for stocks like AZTA and its peers—it's a practical way to incorporate data-backed automation into my strategy.
What's Ahead for AZTA Investors
Looking forward, I'm watching Azenta's ability to improve operational execution, including the Multiomics transformation, leadership enhancements, and cost discipline. The Q3 fiscal 2026 earnings, due in early August, will be a critical test for demand recovery and meeting guidance. Analyst consensus maintains an Outperform rating with an average price target of $35–$41, though some recent cuts signal caution. Sector headwinds like biotech funding pressures and economic sensitivity remain, but opportunities persist in recurring revenues from sample repositories and consumables. Keep an eye on the B Medical Systems divestiture and the extension of the long-range plan to 2029 as additional factors to monitor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Contributor
AZTA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for AZTA turned positive on July 22, 2026. Looking at past instances where AZTA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 161 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
AZTA broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.085) is normal, around the industry mean (5.071). P/E Ratio (42.431) is within average values for comparable stocks, (146.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.307). Dividend Yield (0.000) settles around the average of (0.017) among similar stocks. P/S Ratio (2.799) is also within normal values, averaging (91.060).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of automation, vacuum and instrumentation solutions
Industry PharmaceuticalsOther
Advertisement